Roche: Exit Equities, Enter Drugs
It's the end of an era for Roche. Long known for its black-box financial dealings, the Swiss group has shut down investment arm Roche Finance and declared a renewed focus on its Pharma and Diagnostics businesses. The bold bid for transparency hasn't come cheap, but it's timely. Transparency is all the rage, and for the first time in years, Roche has something in its pipeline to point to.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.